Sanofi
Fc variant antibodies and their uses

Abstract:

The invention relates to antibodies directed to .alpha.2.beta.1 integrin and their uses, including humanized anti-alpha 2 (.alpha.2) integrin antibodies and methods of treatment with anti-.alpha.2 integrin antibodies. More specifically the present invention relates to humanized anti-.alpha.2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.